Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The CD48 gene encodes a cell surface glycoprotein that belongs to the CD2 subset of the signaling lymphocytic activation molecule (SLAM) family. The protein is GPI-anchored, meaning it is covalently attached to the outer leaflet of the plasma membrane via a glycosylphosphatidylinositol (GPI) moiety rather than spanning the membrane through a transmembrane domain. Its extracellular region contains a single N-terminal Ig-like V-set domain, which is essential for ligand interactions. Because CD48 lacks a cytoplasmic domain, it cannot directly transduce signals and relies on cooperation with other transmembrane signaling molecules for functional activity.
CD48 exhibits a broad expression profile, present on most hematopoietic cells including T cells, B cells, NK cells, dendritic cells, and granulocytes, as well as on some non-hematopoietic cells, such as endothelial cells. The gene undergoes alternative splicing, producing multiple isoforms and adding complexity to its functional regulation. Additionally, its GPI anchor can be cleaved by specific phospholipases, generating soluble CD48 that may participate in long-range intercellular communication.
CD48 functions as a key co-stimulatory and adhesion molecule, mediating interactions in trans or cis that are critical for immune synapse formation and lymphocyte activation. While it cannot signal on its own, CD48 serves as a ligand-presenting molecule for multiple receptors, most notably 2B4 (CD244). 2B4 is expressed on NK cells and cytotoxic T cells, and its engagement with CD48 triggers phosphorylation of 2B4's intracellular immunoreceptor tyrosine switch motifs, recruiting signaling adaptors such as SAP (SLAM-associated protein). In the presence of SAP, this interaction transmits activating signals, enhancing NK and T cell cytotoxicity, cytokine production, and immune synapse stability, thus boosting clearance of virus-infected or tumor cells. In SAP-deficient conditions, however, the same interaction can deliver inhibitory signals, explaining certain immunodeficiency disease mechanisms.
Figure 1. CD244 is a transmembrane receptor that binds CD48 with high affinity. (Sun L, et al., 2021)
CD48 also interacts directly with CD2 on T cells, strengthening T cell–antigen-presenting cell adhesion and facilitating recruitment of LCK and LAT to the TCR/CD3 complex, lowering activation thresholds and amplifying TCR signaling. Through these multifaceted interactions, CD48 acts as a bridge between innate and adaptive immunity, finely tuning the initiation, strength, and resolution of immune responses.
CD48's clinical importance lies in its association with immunodeficiency, tumor immunity, and potential therapeutic targeting. A clear example is X-linked lymphoproliferative disease type 1 (XLP1), caused by mutations in the SH2D1A gene encoding SAP. Without functional SAP, interactions between 2B4 on cytotoxic lymphocytes and CD48 on target cells switch from activating to strongly inhibitory, preventing NK and CD8+ T cells from effectively eliminating EBV-infected B cells, leading to fatal infectious mononucleosis, lymphoma, or immunoglobulin deficiencies. This highlights the critical role of the CD48–2B4–SAP axis in controlling herpesvirus infections and identifies it as a diagnostic and therapeutic target in XLP1.
In tumor immunity, CD48 is highly expressed on various hematologic malignancies and some solid tumors, presenting potential avenues for immunotherapy. Tumor-associated CD48 may over-engage 2B4 on effector cells, exhausting or dysregulating NK and T cell responses, thus promoting immune evasion. Targeted therapies, including CD48-specific antibodies capable of antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP), are being explored. Its GPI-anchor makes CD48 a promising target for CAR-T or bispecific antibody design.
CD48 also serves as an entry receptor for some viruses, such as measles virus, further emphasizing its role in host-pathogen interactions. Continued research into CD48 regulation across immune cell subsets and disease contexts may inform strategies to enhance immunity against infections and tumors or inhibit pathological immune responses in autoimmune or lymphoproliferative disorders.
References
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.